In this GEN webinar, sponsored by Carterra, we will demonstrate how modern day high-throughput surface plasmon resonance (HT-SPR™) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This essentially combines screening and detailed characterization in the same step, condensing months of work into days.
In this GEN webinar, sponsored by R&D Systems, we will learn about the cellular and systemic conditions that regulate the hyper-inflammatory condition known as cytokine storm syndrome (CSS). This disorder has seen renewed interest, as it has been associated with a number of SARS-CoV-2 infections, an area that will also be discussed.
In this GEN webinar, sponsored by Domain Therapeutics, we will discuss how the use of enhanced bystander bioluminescence energy transfer (ebBRET) biosensors and tag-free G protein coupled receptors (GPCRs) can help empower the discovery of next-gen therapeutics.
In this GEN webinar, sponsored by Sartorius Stedim Biotech, we will hear how application of modern bottle and flask closure technologies in combination with machine automation can compress a cell expansion process map to bring about a low-risk, streamlined workflow with reduced operating costs.
Join us for Episode 4 of GEN Live, sponsored by Tecan. In this live zoom event we discuss the state of vaccine development for COVID-19. We evaluate the front-runners, explore the potential of RNA vaccines, ponder the challenges of manufacturing, and tackle questions about herd immunity.
In this GEN webinar, sponsored by Lonza, we will examine initial strategies to optimize the amino acid sequence of biotherapeutic molecules, along with techniques to maximize product quality through expression vector design. One tool, GS piggyBac™, which can help improve expression levels, especially for more complex, next-generation biologics, will be discussed.
REGISTER NOW Broadcast Date: February 5, 2019Time: 8:00 am PT, 11:00 am ET, 17:00 CET Antibody-drug conjugates select ADCs) were initially developed to provide a selective targeting mechanism...
In this GEN webinar, we will hear a series of presentations highlighting some of the high-quality bioscience research that is emerging from various industries across Iowa. Specifically, two of our presenters will discuss not only the manufacturing and testing capabilities to advance new vaccine candidates into clinical trials, but also some of the technological advances, facilities, and infrastructure that are being applied to pandemic preparedness and rapid vaccine development.